Alder Biopharmaceuticals, Inc. announced new one-year efficacy data from the PROMISE 1 Phase 3 clinical trial in patients with episodic migraine. The data demonstrate that patients experienced even further reductions in monthly migraine days (MMDs) following the third and fourth quarterly infusions of eptinezumab, Alder’s lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide (CGRP). Highlights from PROMISE 1 Trial Following Third and Fourth Eptinezumab Infusions: Following the first quarterly infusion, patients treated with 300 mg experienced 4.3 fewer MMDs from a baseline of 8 MMDs, compared to 3.2 fewer MMDs for placebo from baseline (p value = 0.0001). At one year after the third and fourth quarterly infusions, patients treated with 300 mg experienced further gains in efficacy with a reduction of 5.2 fewer MMDs compared to 4.0 fewer MMDs for placebo-treated patients. Approximately, 31% of patients achieved, on average per month, 100% reduction of migraine days from baseline compared to approximately 21% for placebo. This means that almost one-third of patients, on average, experienced monthly migraine freedom when treated with 300 mg of eptinezumab. There were no new safety findings observed with the third and fourth quarterly infusions. The observed safety profile for PROMISE 1, to date, is consistent with previously reported eptinezumab studies. The most commonly reported adverse events occurring at an incidence of 2.0% or greater across all eptinezumab treatment groups and greater than placebo were: upper respiratory tract infection (10.5%), nasopharyngitis (common cold) (6.8%), fatigue (3.2%), diarrhea (2.3%) and oropharyngeal (mouth) pain (2.0%).